PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Verona progresses PhII trial of COPD inhaler

Verona Pharma is progressing a Phase II trial of new inhaler formulation of ensifentrine following a coronavirus pandemic-induced pause.

The company said it has now kicked off the second, multiple dose, part of a Phase II trial to evaluate the pressurised metered-dose inhaler (pMDI) formulation of ensifentrine in patients with moderate to severe chronic obstructive pulmonary disease (COPD).

The move follows positive efficacy and safety data from the first, single dose, part of the study (Part A) in 40 patients with moderate to severe COPD, announced by the company earlier this year, which showed a “statistically significant and clinically meaningful increase in lung function”, as measured by forced expiratory volume in one second (FEV1) versus placebo.

Verona had postponed initiation of Part B of the study due to concerns for the safety of patients and study staff because of the COVID-19 pandemic, but following an assessment of local infection rates and control measures is now continuing as planned.

“We are pleased to start the multiple dose part of this pMDI study and expect the results in the first half of 2021,” said David Zaccardelli, the company’s president and chief executive.

“Data from the single dose part of this pMDI study are very encouraging and consistent with data from Phase II clinical trials with our nebulised and dry powder inhaler formulations of ensifentrine.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026